CORT Quote, Financials, Valuation and Earnings

ADMA Biologics has a net margin of 25.86% compared to Corcept Therapeutics's net margin of 29.96%. Corcept Therapeutics's return on equity of 25.77% beat ADMA Biologics's return on equity of 39.59%.

Corcept Therapeutics has a consensus price target of --, signalling upside risk potential of 44.9%. On the other hand ADMA Biologics has an analysts' consensus of $24.62 which suggests that it could grow by 32.64%. Given that Corcept Therapeutics has higher upside potential than ADMA Biologics, analysts believe Corcept Therapeutics is more attractive than ADMA Biologics.

Corcept Therapeutics has a beta of 0.555, which suggesting that the stock is 44.46% less volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.759, suggesting its less volatile than the S&P 500 by 24.057%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $182.5M, which are larger than ADMA Biologics quarterly revenues of $119.8M. Corcept Therapeutics's net income of $47.2M is higher than ADMA Biologics's net income of $35.9M. Notably, Corcept Therapeutics's price-to-earnings ratio is 41.02x while ADMA Biologics's PE ratio is 66.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 9.16x versus 11.51x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 25.86% compared to Corcept Therapeutics's net margin of 34.1%. Corcept Therapeutics's return on equity of 25.77% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Corcept Therapeutics has a consensus price target of --, signalling upside risk potential of 44.9%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $32.13 which suggests that it could grow by 40.9%. Given that Corcept Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Catalyst Pharmaceuticals.

Corcept Therapeutics has a beta of 0.555, which suggesting that the stock is 44.46% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.251%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $182.5M, which are larger than Catalyst Pharmaceuticals quarterly revenues of $128.7M. Corcept Therapeutics's net income of $47.2M is higher than Catalyst Pharmaceuticals's net income of $43.9M. Notably, Corcept Therapeutics's price-to-earnings ratio is 41.02x while Catalyst Pharmaceuticals's PE ratio is 19.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 9.16x versus 6.03x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 25.86% compared to Corcept Therapeutics's net margin of -104.98%. Corcept Therapeutics's return on equity of 25.77% beat Ionis Pharmaceuticals's return on equity of -93.21%.

Corcept Therapeutics has a consensus price target of --, signalling upside risk potential of 44.9%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.32 which suggests that it could grow by 79.82%. Given that Ionis Pharmaceuticals has higher upside potential than Corcept Therapeutics, analysts believe Ionis Pharmaceuticals is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.555, which suggesting that the stock is 44.46% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.485%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $182.5M, which are larger than Ionis Pharmaceuticals quarterly revenues of $133.8M. Corcept Therapeutics's net income of $47.2M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Corcept Therapeutics's price-to-earnings ratio is 41.02x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 9.16x versus 6.20x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of 25.86% compared to Corcept Therapeutics's net margin of -172.04%. Corcept Therapeutics's return on equity of 25.77% beat Madrigal Pharmaceuticals's return on equity of -89.04%.

Corcept Therapeutics has a consensus price target of --, signalling upside risk potential of 44.9%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 11.88%. Given that Corcept Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Madrigal Pharmaceuticals.

Corcept Therapeutics has a beta of 0.555, which suggesting that the stock is 44.46% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.363, suggesting its less volatile than the S&P 500 by 136.278%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $182.5M, which are larger than Madrigal Pharmaceuticals quarterly revenues of $62.2M. Corcept Therapeutics's net income of $47.2M is higher than Madrigal Pharmaceuticals's net income of -$107M. Notably, Corcept Therapeutics's price-to-earnings ratio is 41.02x while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 9.16x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.